Logo image of IMAB

I-MAB-SPONSORED ADR (IMAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMAB - US44975P1030 - ADR

4.63 USD
-0.01 (-0.22%)
Last: 10/29/2025, 8:00:02 PM
4.72 USD
+0.09 (+1.94%)
After Hours: 10/29/2025, 8:00:02 PM
Fundamental Rating

3

Overall IMAB gets a fundamental rating of 3 out of 10. We evaluated IMAB against 533 industry peers in the Biotechnology industry. IMAB has a great financial health rating, but its profitability evaluates not so good. IMAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMAB had negative earnings in the past year.
In the past 5 years IMAB reported 4 times negative net income.
In the past 5 years IMAB reported 4 times negative operating cash flow.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

IMAB's Return On Assets of -18.22% is fine compared to the rest of the industry. IMAB outperforms 77.61% of its industry peers.
IMAB has a better Return On Equity (-19.14%) than 84.70% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IMAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMAB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMAB has more shares outstanding
IMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

IMAB has an Altman-Z score of 23.66. This indicates that IMAB is financially healthy and has little risk of bankruptcy at the moment.
IMAB has a better Altman-Z score (23.66) than 91.60% of its industry peers.
IMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.66
ROIC/WACCN/A
WACC8.67%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 22.86 indicates that IMAB has no problem at all paying its short term obligations.
IMAB has a Current ratio of 22.86. This is amongst the best in the industry. IMAB outperforms 95.90% of its industry peers.
IMAB has a Quick Ratio of 22.86. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
IMAB's Quick ratio of 22.86 is amongst the best of the industry. IMAB outperforms 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 22.86
Quick Ratio 22.86
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.81% over the past year.
IMAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.68% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

IMAB's earnings are expected to grow with 14.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.17%
EPS Next 3Y14.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

I-MAB-SPONSORED ADR

NASDAQ:IMAB (10/29/2025, 8:00:02 PM)

After market: 4.72 +0.09 (+1.94%)

4.63

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20/bmo
Earnings (Next)04-01 2026-04-01/amc
Inst OwnersN/A
Inst Owner Change211.29%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap533.68M
Revenue(TTM)N/A
Net Income(TTM)-37.71M
Analysts85
Price Target8.5 (83.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.51%
Min EPS beat(2)-61.76%
Max EPS beat(2)54.75%
EPS beat(4)1
Avg EPS beat(4)-12.75%
Min EPS beat(4)-61.76%
Max EPS beat(4)54.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.05%
PT rev (3m)38.89%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)39.39%
EPS NY rev (3m)61.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.86
Quick Ratio 22.86
Altman-Z 23.66
F-ScoreN/A
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3Y34.96%
EBIT Next 5Y74.68%
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A

I-MAB-SPONSORED ADR / IMAB FAQ

What is the fundamental rating for IMAB stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMAB.


Can you provide the valuation status for I-MAB-SPONSORED ADR?

ChartMill assigns a valuation rating of 0 / 10 to I-MAB-SPONSORED ADR (IMAB). This can be considered as Overvalued.


Can you provide the profitability details for I-MAB-SPONSORED ADR?

I-MAB-SPONSORED ADR (IMAB) has a profitability rating of 1 / 10.


What is the financial health of I-MAB-SPONSORED ADR (IMAB) stock?

The financial health rating of I-MAB-SPONSORED ADR (IMAB) is 8 / 10.


What is the expected EPS growth for I-MAB-SPONSORED ADR (IMAB) stock?

The Earnings per Share (EPS) of I-MAB-SPONSORED ADR (IMAB) is expected to grow by 89.8% in the next year.